August 2013 Volume 20 Issue 3

Rationale for Selection of Dissolution Media: Three Case Studies Nikoletta Fotaki1, William Brown2, Jianmei Kochling3, Hitesh Chokshi4, Hai Miao5, Kin Tang4, and Vivian Gray6 1University of Bath, Bath, UK 2United States Pharmacopeial Convention, Rockville, MD, USA 3Genzyme, Waltham, MA, USA 4Roche, Nutley, NJ, USA 5Vertex Pharmaceuticals, Cambridge, MA, USA 6V. A. Gray Consulting, Inc., Hockessin, DE, USA Enhancement in Dissolution Rate of Piroxicam by Two Micronization Techniques J. Varshosaz, A. Khajavinia, M. Ghasemlu, E. Ataei, K. Golshiri, and I. Khayam Department of Pharmaceutics, Faculty of Pharmacy and Novel Drug Delivery Systems Research Center, Isfahan University of Medical Sciences, Isfahan, Iran A Dissolution Test for Finasteride in Immediate-Release Capsules Olimpia Maria Martins Santos, Ana Laura Araújo Santos, Gislaine Ribeiro Pereira, Rudy Bonfilio, and Magali Benjamim de Araújo Faculdade de Ciências Farmacêuticas, Universidade Federal de Alfenas, Rua Gabriel Monteiro da Silva, Alfenas-MG, Brazil The Effect of Probe Path Length Calibration on Dissolution Tests Performed with a Fiber-Optic In Situ Dissolution Test System Pingping Xu, Xinxia Li, Li Li, Yang Liu, Bin Kong, Kun Nie, and Jian Chen School of Pharmacy, Xinjiang Medical University, Xinjiang, Urumqi, China Comparison of the Solubility and Dissolution of Drugs in Fasted-State Biorelevant Media (FaSSIF and FaSSIF-V2) Mathew Leigh, Bastian Kloefer, and Michael Schaich Biorelevant.com, Capital Business Centre, Croydon, Surrey, United Kingdom Meeting Report: AAPS Workshop on Dissolution Testing and Bioequivalence Vivian A. Gray Dissolution Technologies, Hockessin, DE, USA Updates on USP Activities Related to Dissolution, Disintegration, and Drug Release Margareth R. C. Marques and William Brown U. S. Pharmacopeia, Rockville, MD, USA Question & Answer Section Margareth Marques and William Brown United States Pharmacopeia, Rockville,MD